Patents by Inventor Kousuke Hidaka

Kousuke Hidaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IP6K inhibitors
    Patent number: 10968178
    Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: April 6, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshito Terao, Masashi Takahashi, Ryoma Hara, Kousuke Hidaka, Hideki Furukawa, Takeshi Yamasaki, Shizuo Kasai
  • IP6K INHIBITORS
    Publication number: 20200377458
    Abstract: The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for—diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like.
    Type: Application
    Filed: March 29, 2017
    Publication date: December 3, 2020
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Yoshito TERAO, Masashi TAKAHASHI, Ryoma HARA, Kousuke HIDAKA, Hideki FURUKAWA, Takeshi YAMASAKI, Shizuo KASAl
  • Heterocyclic compound
    Patent number: 10357484
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 23, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Masashi Toyofuku, Kousuke Hidaka
  • Heterocyclic compound
    Patent number: 10308643
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masashi Toyofuku, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Kousuke Hidaka
  • HETEROCYCLIC COMPOUND
    Publication number: 20190008836
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 10, 2019
    Inventors: Akira KAIEDA, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Masashi TOYOFUKU, Kousuke HIDAKA
  • Heterocyclic compound
    Patent number: 10081624
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: September 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Masashi Toyofuku, Kousuke Hidaka
  • HETEROCYCLIC COMPOUND
    Publication number: 20180222896
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 9, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Noaki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Mashashi Toyofuku, Kousuke Hidaka
  • HETEROCYCLIC COMPOUND
    Publication number: 20170015655
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Akira KAIEDA, Masashi TOYOFUKU, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Kousuke HIDAKA
  • Aromatic ring compound
    Patent number: 9073864
    Abstract: Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: July 7, 2015
    Assignee: Takeda Pharmaceutical Company Limted
    Inventors: Minoru Sasaki, Hideki Furukawa, Kousuke Hidaka, Kyoko Toyofuku, Takatoshi Yogo, Toshiki Murata
  • AROMATIC RING COMPOUND
    Publication number: 20150152052
    Abstract: Provided is an aromatic ring compound having a glucagon antagonistic action, which is useful for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has a superior glucagon antagonistic action, and is useful as a glucagon antagonist, a glucose production inhibitor or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: March 28, 2013
    Publication date: June 4, 2015
    Inventors: Minoru Sasaki, Hideki Furukawa, Kousuke Hidaka, Kyoko Toyofuku, Takatoshi Yogo, Toshiki Murata